Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus chemotherapy and immune checkpoint inhibitor for advanced squamous non-small cell lung cancer
ChiCTR2300070009Phase 4Not yet recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of endostar in Pulmonary squamous cell carcinoma, sponsored by Yancheng First People's Hospital. Primary endpoints: progression-free survival and objective response rate. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2300070009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070009.